The investigation leverages sophisticated transgenic mouse models expressing pathological αS variants and direct injections of PD-derived αS fibrils into the mesentery to mimic gut-originating αS pathology. Intriguingly, these models reveal that αS aggregation begins within the enteric nervous system (ENS), concomitant with gastrointestinal dysfunction characterized by increased gut transit time. This aligns closely with Braak staging hypotheses, which propose that in body-first PD phenotypes, αS pathology originates in peripheral tissues, such as the gut, before ascending to the central nervous system (CNS).

Key to the process are the ME-Macs, which demonstrate elevated uptake of phosphorylated αS at serine 129 (s129p+), a pathological hallmark. Despite their established role in maintaining ENS homeostasis, these macrophages are shown to harbor significant amounts of misfolded αS, implicating them as both facilitators and modulators of αS protein aggregation. Notably, ME-Macs upregulated autophagic and lysosomal clearance pathways, yet paradoxically appeared to foster a microenvironment conducive to αS aggregate accumulation—highlighting a dualistic function that may underpin early-stage synucleinopathy.

Targeted depletion experiments further illustrate the indispensability of ME-Macs in disease progression. When selectively ablated, these macrophages substantially mitigate the spread of s129p+ αS inclusions from the ENS into the CNS as well as attenuate motor dysfunction in murine models. Despite minor collateral reductions in eosinophil and monocyte populations, the findings underscore ME-Macs as crucial nodes for αS propagation, possibly through their expression of PD-associated risk genes such as Gba1, Lrrk2, Vps35, and Ctsd—genes heavily implicated in lysosomal functioning and protein degradation.

Beyond macrophage-centric mechanisms, the study reveals a potent immunological axis involving T cell expansion. ME-Macs were found to significantly influence the local proliferation of CD3+ T cells in the ENS, which subsequently migrate to CNS regions pertinent to PD neuropathology, notably the dorsal striatum and lateral ventricles. This T cell trafficking phenomenon supports a paradigm where αS pathology incites neuroimmune crosstalk, potentially exacerbating neurodegeneration through sustained inflammatory milieu and antigen presentation dynamics.

Pharmacological intervention with fingolimod, a T cell trafficking inhibitor, demonstrated neuroprotective effects by reducing αS spread and corresponding neurodegeneration in PD mouse models. This not only affirms the pathological role of T cells in synucleinopathy progression but opens avenues for immunomodulatory therapeutic strategies. Nonetheless, the complex, systemic immunoregulatory effects of such drugs warrant further elucidation to decipher specificity within PD pathology.

Elucidating the cellular communication channels, the study highlights that ME-Macs upregulate major histocompatibility complex class II (MHCII) molecules in response to αS pathology, positioning them as probable antigen-presenting entities capable of modulating T cell responses. However, the potential interplay with dendritic cells—known professional antigen presenters—remains an open question. It is conceivable that ME-Macs transfer αS antigens to dendritic cells to facilitate T cell priming, but definitive mechanisms await discovery.

Furthermore, TGFβ signaling within ME-Macs emerged as a pivotal factor in governing T cell expansion triggered by αS. The attenuation of TGFβ expression in ME-Macs corresponds with reduced T cell proliferation, underscoring a cytokine-mediated axis crucial for immune modulation. Given TGFβ’s known influence on T cell differentiation into regulatory or inflammatory phenotypes, its role in synucleinopathy-associated immune dysregulation represents a promising therapeutic target.

The identification of ME-Macs’ unique perivascular gene signatures resembling CNS border-associated macrophages also hints at conserved immune regulatory functions across the gut–brain interface. This resemblance could explain their specialized roles in recruiting and activating CD4+ T cells within neuroimmune niches, a process previously implicated in αS-overexpressing models. It further heightens the need to explore whether such tissue-resident macrophages universally contribute to neurodegeneration via immune mechanisms.

Importantly, this work contextualizes environmental and intrinsic triggers for αS aggregation in human gut tissue, including pesticide exposure and viral infections known to elevate enteric αS expression and phosphorylation. Ageing similarly contributes to progressive αS modifications, suggesting a multifactorial etiology that primes ME-Macs and associated immune cells for pathological engagement. These exogenous and endogenous factors may serve as initial catalysts for the cascade leading to PD.

While the model centers on direct pathogenic αS administration, the study acknowledges the elusive endogenous triggers driving initial αS misfolding events in humans. Future research must decode this initial seeding, illuminating preventive strategies for PD. Integration of known PD risk genes within macrophage lysosomal pathways accentuates the biological convergence toward impaired αS clearance as a fundamental disease mechanism.

Finally, the clinical implications of these findings are profound. By placing ME-Macs at the forefront of αS pathology transmission and immune modulation, the study not only reshapes the understanding of gut–brain axis involvement in PD but also proposes novel diagnostic and therapeutic opportunities. Targeting ME-Macs and their crosstalk with T cells could permit interception of disease progression at early, potentially reversible stages, transforming the landscape of PD management and offering hope for millions globally.

Subject of Research:
Intestinal macrophages and their role in modulating α-synuclein pathology and immune responses along the gut–brain axis in Parkinson’s disease models.

Article Title:
Intestinal macrophages modulate synucleinopathy along the gut–brain axis.

Article References:
De Schepper, S., Konstantellos, V., Conway, J.A. et al. Intestinal macrophages modulate synucleinopathy along the gut–brain axis. Nature (2026). https://doi.org/10.1038/s41586-025-09984-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-025-09984-y

The heart of this collaboration lies in the deployment of GemPharmatech’s NeoMab® platform, a next-generation transgenic mouse model engineered for the swift and efficient identification of fully human therapeutic antibodies. The NeoMab® model has revolutionized antibody discovery by carrying an extensive repertoire of human immunoglobulin variable genes in a BALB/c mouse genetic background, eliminating the traditionally laborious step of sequence humanization. This innovation dramatically reduces development timelines and minimizes immunogenicity concerns that have historically challenged antibody therapeutics.

Memorial Sloan Kettering researchers will tap into NeoMab®’s sophisticated design to generate diverse arrays of high-affinity, fully human antibodies. Unlike previous models, which required extensive post-discovery modifications to humanize antibodies derived from murine sequences, NeoMab® mice produce antibodies with inherently human variable regions. This capacity aligns with current demands for biomarkers and immunotherapies that avoid adverse immune responses, accelerating translation from bench to bedside.

Dr. Xiang Gao, founder of GemPharmatech, emphasized the transformational potential of this alliance, remarking that their mission is deeply rooted in enabling pioneering biomedical research via innovative mouse models and technologies. He expressed enthusiasm about melding MSK’s scientific excellence with NeoMab®’s capabilities to accelerate discovery pipelines for novel cancer therapeutics, potentially altering the landscape of oncology drug development.

The NeoMab® platform’s unique genetic engineering involves the humanization of immunoglobulin loci, introducing the full human heavy and kappa light chain variable region gene repertoires along with relevant regulatory elements. Embedded in a BALB/c background—a well-characterized murine strain—the platform offers researchers a robust and reliable system that faithfully recapitulates human antibody diversity and affinity maturation processes, facilitating the generation of therapeutic candidates with optimal specificity and potency.

Memorial Sloan Kettering’s expertise in oncology research, combined with access to such a powerful antibody discovery platform, promises to accelerate identification of antibodies against high-value and challenging cancer targets. This project is poised to hone therapeutic antibodies that can disrupt tumorigenic pathways, modulate immune checkpoints, or enhance immune cell infiltration within the tumor microenvironment—areas of investigation paramount to advancing precision oncology.

Beyond oncology, the collaboration exemplifies a broader shift in preclinical drug discovery, where sophisticated genetically engineered models supplant older, less predictive systems. The ability to generate fully human antibodies in an immunologically competent host reduces the risk of immunogenicity upon clinical application, thereby improving safety profiles and success rates in later-stage clinical trials.

Dr. Brandy Wilkinson, CEO of GemPharmatech, highlighted the strategic importance of this partnership in fulfilling the company’s mission to furnish the global scientific community with state-of-the-art tools that accelerate drug innovation. She underlined the honor and responsibility of supporting MSK’s trailblazing oncology programs, reinforcing that the NeoMab® platform will be instrumental in expediting antibody programs that are poised to transform patient care worldwide.

GemPharmatech’s extensive portfolio, anchored by the world’s largest library of genetically engineered mouse models (GEMMs), grants unparalleled versatility to researchers. With access to over 25,000 mouse strains—including knockout, conditional knockout, humanized, and immunodeficient variants—the company has established itself as a vital partner in the discovery and validation of therapeutic candidates across multiple complex disease areas.

Innovations like the NeoMab® model illustrate the powerful synergy between genetic engineering and immunology, facilitating breakthroughs not merely in antibody discovery but also in understanding immune regulation, antigen presentation, and tumor immune evasion. These insights hold transformative potential for designing combination therapies that leverage both immunomodulation and direct tumor targeting.

As the collaboration advances, the scientific community will be keenly observing the generation, characterization, and preclinical efficacy of novel fully human antibodies emerging from this alliance. Success in this domain promises not only to shorten discovery timelines but also to elevate the quality and manufacturability of antibody drugs entering clinical evaluation, setting new standards for therapeutic innovation.

Ultimately, this partnership between GemPharmatech and Memorial Sloan Kettering exemplifies the convergence of technological innovation and rigorous scientific expertise in pursuit of better cancer treatments. By harnessing next-generation genetically engineered models like NeoMab®, the collaboration stands as a beacon of hope for patients and researchers alike, accelerating the advent of transformative antibody-based therapeutics in oncology.

Subject of Research: Not applicable
Article Title: [Information not provided]
News Publication Date: [Information not provided]
Web References: https://en.gempharmatech.com/
Keywords: Oncology, Cancer research